Zhejiang Cancer Hospital: Carcinoma trials

The registry lists 41 Carcinoma studies with Zhejiang Cancer Hospital as lead sponsor. 15 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 2Phase 2 25Phase 3 4Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPCNot yet recruitingNCT06752382Phase 2
• Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06741020Phase 1/2
• Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06422858Phase 2
• Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal CarcinomaNot yet recruitingNCT06364826Phase 2
• A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.RecruitingNCT06349044Not applicable
• A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCCRecruitingNCT06190639Phase 2
• Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular CarcinomaRecruitingNCT05971199Phase 2
• Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
• Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2
• A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell CarcinomaRecruitingNCT05705583
• SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPCRecruitingNCT05652192Phase 2
• Radiotherapy Combined With Endostatin and Capecitabine for NPCRecruitingNCT05514275Phase 2
• Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCCRecruitingNCT05507411Phase 2
• Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160
• PET/MR in Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT03657017Not applicable
• SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract CarcinomaSuspendedNCT06199882Phase 2
• Mechanism of Gastric Signet Ring Cell Carcinoma Based on MicroproteomicsActive, not recruitingNCT05985577
• Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05232552Phase 2
• Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular CarcinomaStatus unknownNCT05053386Not applicable
• Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCCStatus unknownNCT05007587Early Phase 1
• TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)Status unknownNCT04560751
• Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04506138Phase 1/2
• A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.SuspendedNCT04084158Phase 2
• TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT04066543Phase 2
• Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell CarcinomaStatus unknownNCT04049344Phase 2
• Tegio Consolidation Therapy for NPC Patients With High Risk of MetastasisStatus unknownNCT03904225Phase 2
• Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined ChemotherapyStatus unknownNCT03647527
• TOMO Versus IMRT in Nasopharyngeal Carcinoma PatientsStatus unknownNCT03588403
• Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma PatientsStatus unknownNCT03411954
• Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)Status unknownNCT03213587Phase 2
• Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03058432Phase 2
• Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT03025958Phase 2
• Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal CarcinomaStatus unknownNCT03015727Phase 3
• A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma PatientsStatus unknownNCT02948699Phase 4
• A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT02878889Phase 2
• Comparable Study of Different Radiation Dose in Esophageal CarcinomaStatus unknownNCT01937208Phase 3
• Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT01915134Phase 3
• Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT01688700Phase 2
• Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal CarcinomaStatus unknownNCT01612286Phase 2
• Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal CarcinomaStatus unknownNCT01536223Phase 3
• Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer PatientsCompletedNCT01258192Phase 2